Division of Gastroenterology, Duke Clinical Research Institute, Duke University School of Medicine, Room 0311 Terrace Level 2400 Pratt Street, Durham, NC 27715, USA. Electronic address: firstname.lastname@example.org.
In May 2011, the protease inhibitors boceprevir and telaprevir were approved in combination with peginterferon-α and ribavirin for the treatment of genotype 1 chronic hepatitis C virus infection in the United States. These regimens brought substantial improvements in sustained virologic response rates, especially for treatment-naïve patients. This article reviews the approach to therapy with these genotype 1 treatment-naïve patients.